Long-acting GnRH agonist (GnRHa) is usually used in patients with adenomyosis receiving ART treatment, because it can induce and maintain a hypoestrogenic state by suppressing gonadotropin secretion (13). This evidence concerns the gene GNRH1 and adenomyosis.